| pubmed-article:1519035 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1519035 | lifeskim:mentions | umls-concept:C0034699 | lld:lifeskim |
| pubmed-article:1519035 | lifeskim:mentions | umls-concept:C0011847 | lld:lifeskim |
| pubmed-article:1519035 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:1519035 | lifeskim:mentions | umls-concept:C1527148 | lld:lifeskim |
| pubmed-article:1519035 | lifeskim:mentions | umls-concept:C0284559 | lld:lifeskim |
| pubmed-article:1519035 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:1519035 | pubmed:dateCreated | 1992-10-6 | lld:pubmed |
| pubmed-article:1519035 | pubmed:abstractText | The effects of the administration of the recently discovered immunosuppressant 15-Deoxyspergualin (DSP) on the development of insulin-dependent diabetes mellitus (IDDM) in diabetes-prone BB rats were studied. The data show that 2 mg/kg body weight DSP, administered six times a week from the 30th day up to the 105th day of age, significantly reduced the incidence of diabetes in diabetes-prone BB rats as compared with the PBS-injected controls. The drug was also able to reduce the signs of pancreatic insulitis and the percentages of W3/25+ and OX6+ splenocytes. Interruption of the treatment resulted in a later onset of diabetes in a high percentage of animals within 41 days. These findings suggest that 15-DSP may temporarily reverse the pathogenic mechanisms leading to beta cell destruction and autoimmune diabetes in a well-known experimental model of human insulin-dependent diabetes mellitus. | lld:pubmed |
| pubmed-article:1519035 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1519035 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1519035 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1519035 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1519035 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1519035 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1519035 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1519035 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:1519035 | pubmed:issn | 0300-9475 | lld:pubmed |
| pubmed-article:1519035 | pubmed:author | pubmed-author:NicolettiFF | lld:pubmed |
| pubmed-article:1519035 | pubmed:author | pubmed-author:SchorlemmerH... | lld:pubmed |
| pubmed-article:1519035 | pubmed:author | pubmed-author:MeroniP LPL | lld:pubmed |
| pubmed-article:1519035 | pubmed:author | pubmed-author:GrasseEE | lld:pubmed |
| pubmed-article:1519035 | pubmed:author | pubmed-author:LunettaMM | lld:pubmed |
| pubmed-article:1519035 | pubmed:author | pubmed-author:MughiniLL | lld:pubmed |
| pubmed-article:1519035 | pubmed:author | pubmed-author:Di MarcoRR | lld:pubmed |
| pubmed-article:1519035 | pubmed:author | pubmed-author:BarcelliniWW | lld:pubmed |
| pubmed-article:1519035 | pubmed:author | pubmed-author:BorghiM OMO | lld:pubmed |
| pubmed-article:1519035 | pubmed:author | pubmed-author:MentaRR | lld:pubmed |
| pubmed-article:1519035 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1519035 | pubmed:volume | 36 | lld:pubmed |
| pubmed-article:1519035 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1519035 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:1519035 | pubmed:pagination | 415-20 | lld:pubmed |
| pubmed-article:1519035 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:1519035 | pubmed:meshHeading | pubmed-meshheading:1519035-... | lld:pubmed |
| pubmed-article:1519035 | pubmed:meshHeading | pubmed-meshheading:1519035-... | lld:pubmed |
| pubmed-article:1519035 | pubmed:meshHeading | pubmed-meshheading:1519035-... | lld:pubmed |
| pubmed-article:1519035 | pubmed:meshHeading | pubmed-meshheading:1519035-... | lld:pubmed |
| pubmed-article:1519035 | pubmed:meshHeading | pubmed-meshheading:1519035-... | lld:pubmed |
| pubmed-article:1519035 | pubmed:meshHeading | pubmed-meshheading:1519035-... | lld:pubmed |
| pubmed-article:1519035 | pubmed:meshHeading | pubmed-meshheading:1519035-... | lld:pubmed |
| pubmed-article:1519035 | pubmed:meshHeading | pubmed-meshheading:1519035-... | lld:pubmed |
| pubmed-article:1519035 | pubmed:meshHeading | pubmed-meshheading:1519035-... | lld:pubmed |
| pubmed-article:1519035 | pubmed:meshHeading | pubmed-meshheading:1519035-... | lld:pubmed |
| pubmed-article:1519035 | pubmed:meshHeading | pubmed-meshheading:1519035-... | lld:pubmed |
| pubmed-article:1519035 | pubmed:meshHeading | pubmed-meshheading:1519035-... | lld:pubmed |
| pubmed-article:1519035 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1519035 | pubmed:articleTitle | The effects of deoxyspergualin on the development of diabetes in diabetes-prone BB rats. | lld:pubmed |
| pubmed-article:1519035 | pubmed:affiliation | Institute of Internal Medicine, Infectious Diseases and Immunopathology, University of Milan, Italy. | lld:pubmed |
| pubmed-article:1519035 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1519035 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1519035 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1519035 | lld:pubmed |
